These studies have described disruption to apoptotic, senescence, and NF-κB signaling pathways as factors driving therapeutic resistance, and provide evidence suggesting distinct tumor evolutionary dynamics in early vs late relapse cases [8, 22–26]; overall broadening the scope of understanding of rrDLBCL tumor biology. Here, NFKB1 is linked to neoplasm.